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Cost of Lifetime Immunosuppression Coverage for Kidney
Transplant Recipients
Timothy F. Page, Ph.D. and Robert S. Woodward, Ph.D.

On January 1, 2000, Medicare extended
the coverage of immunosuppression medi
cations from 3 years to life for elderly and
disabled kidney transplant recipients. This
research estimates the impact of extending
this lifetime coverage to all kidney transplant
recipients on Medicare’s cash flows. The study
finds that extending coverage to all kidney
transplant recipients would have increased
Medicare’s net cash outflows if the coverage
were extended for patients of all income lev
els. There is evidence that extending coverage
to only patients in the lowest income quartile
could have resulted in a net cost savings
to Medicare.
intrODUCtiOn
While Medicare in the U.S. only added
a prescription medication option to its
benefit package in 2006, it has provided at
least 1 year coverage of immunosuppres
sion medications for transplant receipients
since 1978. Between 1993 and 1995, Medi
care increased the duration of immuno
suppression medication coverage from 1
to 3 years post transplant for all transplant
recipients. On January 1, 2000, Medicare
effectively provided lifetime immunosup
pression medication coverage to trans
plant receipients over age 65 or disabled,
but the immunosuppression coverage for
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non-disabled transplant (ineligible) recipi
ents under age 65 remained at only 3 years
following transplantation.1
This research estimates the changes in
Medicare’s net cash flow that would have
occurred in the years following 2000 if
Medicare had extended its lifetime cover
age of maintenance immunosuppression
medications to all kidney transplant recipi
ents. Providing lifetime coverage may cre
ate a cash outflow increase determined
by the cost of the medications and the
numbers of transplant recipients whose
coverage would not have been cancelled.
Lifetime coverage, however, may reduce
cash outflows because fewer patients would
have lost their transplanted kidneys and
therefore not have incurred the expenses
of returning to the dialysis. The net impact
of these competing effects is unclear.
We found that if Medicare had extended
lifetime coverage of immunosuppression
medications to all transplant recipients as
of January 1, 2000, Medicare’s cash out
flows would have increased significantly.
Although there would have been sav
ings associated with avoiding graft failure
through increased drug coverage, these
incremental benefits would have been out
weighed by the incremental costs of cover
ing all transplant recipients, most of whom
would have experienced no improvement
in graft survival outcomes.
PreviOUS reSearCH
Other researchers have attempted to esti
mate the costs associated with graft failure
Benefits Improvement and Protection Act (2000), Public Law
106-554.
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(Yen et al., 2004) and address the question
of whether the improvements in graft sur
vival that would occur with lifetime drug
coverage would result in a net savings or
a net cost to Medicare (Gustafsson et al.,
2005). Yen et al. (2004) used a Markov
model to determine the cost effectiveness
of lifetime immunosuppression coverage.
They estimated the costs of graft failure
to be $137,9302 per patient during the first
year after failure. Then they combined this
estimate with estimates of quality adjusted
life year improvements and predicted a net
societal savings of $136 million annually.
While they included benefits in their anal
ysis other than potential cost savings, the
strongest case to be made for extending
lifetime coverage to all transplant recipi
ents would be to show a net cost savings
to Medicare. For this reason, we exam
ined this issue from only the perspective
of Medicare’s cash flows.
Gustafsson and colleagues (2005) ad
dressed the question that we attempted
to answer in this study, that is, whether
lifetime coverage of immunosuppres
sion medication would result in a net sav
ings or a net cost to Medicare. They used
estimates from the U.S. Congressional
Budget Office (1999) to conduct a simu
lation-type analysis of the problem. The
study focused on the 10-year period fol
lowing the introduction of the hypothetical
policy. This required projecting forward
the number of transplants that will occur
in each year. Assuming an annual cost of
immunosuppression drugs of $11,781.56
and an annual post graft failure cost of
$67,7003 per patient, they estimated that
a coverage extension would generate a
net cost of $100 million for patients trans
planted between 2000 and 2004. Also, they
This number includes not only the costs to Medicare, but also
costs to the patient, such as reduced health status.
3 This estimate is consistent with the 2006 estimate published by
the United States Renal Data System (USRDS), and the estimate
found in this study.
2

96

estimated that for the coverage exten
sion to be revenue neutral, between 2006
and 2015, the extended coverage would
need to improve graft survival rates by
2.45 percent.
In this study, we used actual retrospec
tive data to provide estimates of what
would have happened if the coverage ex
tension that was implemented on January
1, 2000, had been extended to all transplant
recipients. Would it have resulted in a
net savings or a net cost to Medicare? An
advantage of our approach is that we have
actual data on the numbers of transplanted
individuals, the graft survival rates, and
the costs associated with graft failure dur
ing the time period considered. Thus, we
do not rely on forecasts that may or may
not accurately describe the problem.
MetHODS
Study Sample
We used data from the USRDS for the
years 1995 to 2003. Our sample included all
first, cadaveric, single organ kidney trans
plant recipients transplanted between 1995
and 2002 with at least $50 in physician/
supplier claims and $5,000 institutional
claims during the first post transplant year.
These claims figures were used to identify
patients for whom Medicare was the pri
mary payer. If this method of identifying
Medicare patients were to exclude valid
cases, this would bias our estimates of
pre- and post-graft failure treatment costs
upward. However, because we identify
the cost savings associated with avoiding
a graft failure as the difference between
pre- and post-graft failure costs, this bias
is likely to be eliminated by taking the preand post-failure difference.4 Of the trans
plants performed between 1995 and 2002
4 We also conduct a sensitivity analysis to determine the extent to

which the analysis is affected by our parameter assumptions.
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for which Medicare was the primary payer,
we were able to match Zip Code median
incomes to 97.4 percent of the patients. The
resulting sample contained 49,091 trans
plants. Of these, 38,861 were identified as
first, single organ, cadaveric transplants.
Throughout this analysis, we divided
our sample into quartiles by Zip Code
median income obtained from the U.S.
Census Bureau (2000). While the USRDS
database does not have information on
individual incomes, many studies used
Zip Code median incomes as a proxy for
individual incomes (Woodward et al.,
2001; 2008). Throughout the analysis, we
refer to our cohorts by income quartile.
Quartile 4 represents the highest Zip
Code median income quartile (defined as
a median income greater than $47,787),
quartile 3 represents the second highest
Zip Code median income quartile (defined
as a median income between $37,407 and
$47,787), quartile 2 represents the third
highest Zip Code median income quartile
(defined as a median income between
$30,335 and 37,407), and quartile 1 repre
sents the lowest Zip Code median income
quartile (defined as a median income
less than $30,335). We use the term high
income to refer to individuals in quartile 4,
while low income refers to individuals in
quartiles 1, 2, or 3.
Although Zip Code median incomes are
only a proxy for actual incomes, this is the
best income measure that can be gener
ated with USRDS data. Further, even if
actual incomes were available, using them
might introduce bias into the analysis of
the relationship between income and graft
survival. For example, individuals who
are healthier may be more likely to work.
This would lead to a correlation between
income and health status that is not related
to access to medications. While Zip Code
incomes are not a perfect proxy for actual

incomes, as long as any potential misclassi
fication is random throughout our sample,
the adoption will not bias our results.
estimation of graft Failure Costs
The difference in daily costs between
patients with functioning grafts and pa
tients who return to dialysis is central to
the analysis. Using the date of graft failure
as the reference point (and graphical ori
gin), we calculated average accumulated
Medicare payment (AAMP) cost curves
for each of the four income quartile. The
AAMPs for each of the four groups were
calculated before and after the first day
post failure. For each day t following the
failure, the average accumulated payments
equaled the average accumulated pay
ments of the previous day plus the average
incremental payments on day t. The aver
age incremental payments on day t were
calculated as the total Medicare payments
made on day t (MPt) divided by the num
ber of individuals remaining uncensored
on day t (nt):
AAMPt = AAMPt-1 + (MPt/ nt)

(1)

where t runs from -730 (2 years before
graft failure) to 1,825 (5 years after graft
failure).
In our analysis of cost saving, we use the
AAMPt estimates specific to each cohort.
To determine the additional daily costs
associated with graft failure, we calculated
the slope of the cost curves for income
quartiles 1, 2, and 3 (these are the cohorts
that would have experienced improved
graft survival rates from lifetime cover
age) before and after graft failure. The
difference in the slopes gave an estimate
of the daily cost differential between pa
tients with functioning grafts and patients
who return to dialysis after graft failure
(Table 1). Additional daily costs were $114,
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Measure
Quartile1
Quartile2
Quartile3

Table 1
Pre- and Post-Graft Failure Cost Differentials by Income Quartile

DailyCostto
MedicarePost
GraftFailure

DailyCostof
PatientWith
Functioning
Graft



Difference
PerDay

Additional
Costs
BeforeGraft
Failure

Additional
CostsAfter
GraftFailure

$162
122
150

$48
50
52

$114
72
98

$21,373
11,767
24,722

$7,564
9,760
9,578

NOTES:PatientsweredividedintoquartilesbasedonthemedianfamilyincomeoftheirZipCodefromthe2000U.S.Census.Quartile1refersto
thelowestZipCodeincomequartile.
SOURCE:Page,T.F.,FloridaInternationalUniversity,andWoodward,R.S.,UniversityofNewHampshire,usingthe2005U.S.RenalData
Systemrelease.

$72, and $98 for income quartiles 1, 2, and
3, respectively.5 In addition to the extra
daily costs associated with graft failure,
payments increased by $21,373, $11,767,
and $24,722 during the year before graft
failure for the bottom three quartiles,
respectively. Because some patients re
main hospitalized immediately following
graft failure, payments associated with
graft failure increased by $7,564, $9,760,
and $9,578 for patients in quartiles 1, 2,
and 3, respectively, in the days following
the graft failure.6 If the graft failures were
to be avoided, Medicare would avoid the
daily cost differential and these extra costs
associated with trying to save the graft.
estimation of graft Sur vival Benefits
To determine the differences in graft
survival rates between high and low
income ineligibles, we constructed KaplanMeier survival curves for each ineligible
income quartile (Figure 1). These KaplanMeier survival curves reflect the probabil
ity of graft survival on each day, adjusted
for censoring. That is, the probability of
graft failure on day t is given by the num
ber of failures on day t divided by the num
ber of patients who are still in the sample
To obtain these estimates, we regressed accumulated costs as
a function of the days pre- and post-failure. The slope estimates
give the daily costs pre and post failure.
6 The intercepts of the cost curves pre and post failure give the
extra costs above and beyond the daily costs of treating a patient
before and after graft failure.
5
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on day t. The Kaplan-Meier survival curve
represents the residual remaining after the
proportion of failures has been subtracted
from 100 percent.
Assuming that the coverage extension
would have taken effect on January 1, 2000,
and would have covered those who had
been transplanted after January 1, 1997, we
then calculated the expected change in the
graft survival rates for low income patients
that would have occurred with lifetime cov
erage. For example, in 1997 there were 636
high income ineligibles transplanted and
1,858 low income ineligibles transplanted.
Assuming that the coverage increase would
have caused the survival of the low income
patients to track the survival for the high
income patients after January 1, 2000, the
Kaplan-Meier plots (Figure 2) illustrates
the survival benefit for patients in income
quartile 1.
Figure 2 illustrates the actual graft sur
vival of low income ineligibles and the
graft survival that the low income ineli
gibles would have experienced had the
coverage extension been applied. In other
words, the slope of the low income sur
vival curves becomes equal to the slope of
the high income survival curve on Janu
ary 1, 2000. Because following each patient
individually from their respective dates
of transplantation to the end of the year
2002 would be computationally difficult,
we assume that each patient transplanted
during a given year was transplanted at the
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Figure 1 �
Probability of Graft Survival Following Transplantation, by Income Quartile �
100
90
80

Percent Survival

70
60
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Actual Quartile 4 Survival
Actual Quartile 3 Survival
Actual Quartile 2 Survival
Actual Quartile 1 Survival

20
10
0
0

365

730

1,095

1,460

1,825

2,190

Days Following Transplant
NOTES:PatientsweredividedintoquartilesbasedonthemedianfamilyincomeoftheirZipCodefromthe2000U.S.Census.
Quartile1referstothelowestZipCodeincomequartile.
SOURCE:Page,T.F.,FloridaInternationalUniversity,andWoodward,R.S.,UniversityofNewHampshire,usingthe2005
U.S.RenalDataSystemrelease.

midpoint of the year, July 1st. Assuming
transplants occurring within a given year
are randomly distributed across the 365
days within that year, this strategy should
yield a reasonable approximation of the
results we would have obtained if we were
able to perform separate calculations for
each of our patients individually. The num
ber of extra grafts saved over the 3-year
period was calculated by applying the pre
dicted survival probability with coverage
to the number of low income ineligible
patients with functioning grafts on January
1, 2000, and subtracting the number of pre
dicted surviving grafts without coverage
each day from January 1, 2000 to Decem
ber 31, 2002. This calculation is done for
each day until December 31, 2002, 3 years
after the coverage increase and 5.5 years
after transplantation.

We repeat this methodology for individ
uals transplanted in 1998, 1999, 2000, 2001,
and 2002. For individuals transplanted
in 1998, the divergence in predicted and
actual survival probabilities for low income
ineligibles occurs at day 730 because Janu
ary 1, 2000, corresponds to 2 years after
transplantation for the 1998 cohort. Simi
larly, the predicted and actual probabilities
diverge for the 1999 cohort at day 365. For
the 2000, 2001, and 2002 cohorts, the sur
vival for high and low income cohorts are
exactly equal because the coverage exten
sion would have already been in effect
when these patients were transplanted.
We assumed that the benefits to the cover
age extension begin even before the expi
ration of the 3-year coverage. The reason
for this assumption is that for patients in
quartile 1, the income related disparity
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Figure 2 �
Actual Graft Survival and Predicted Graft Survival Improvements for Patients in Income Quartile 1
Transplanted in 1997 �
700

Predicted Survival
Actual Survival

650
Coverage Extension
January 1, 2000

Number of Grafts

600
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350
300
July 1,
1997
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July 1,
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July 1,
2000

July 1,
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July 1,
2002

Date Following Transplantation on July 1, 1997
NOTE:PatientsweredividedintoquartilesbasedonthemedianfamilyincomeoftheirZipCodefromthe2000U.S.
Census.Quartile1referstothelowestZipCodeincomequartile.
SOURCE:Page,T.F.,FloridaInternationalUniversity,andWoodward,R.S.,UniversityofNewHampshire,usingthe
2005U.S.RenalDataSystemrelease.

in graft survival occurred sometime dur
ing the second post transplant year. The
reasons for this are unclear. It is possible
that the income related disparity in graft
loss appeared before the expiration of the
third year of coverage because individu
als, knowing that their coverage will expire
anyway, stop taking their medications prior
to the end of the third post transplant year.
Alternatively, they may hoard their medica
tions during this time, taking less than the
recommended doses to save medication for
after the third year of coverage expires.7
Throughout the study, we use conservative estimates of costs
and generous estimates of benefits. Therefore, our estimates
represent best case predictions of what would occur with a
coverage increase.
7

100

accumulation Method
Using the results found in Woodward et
al. (2001; 2008) that Medicare’s 3-year cov
erage extension for all patients and lifetime
coverage of immunosuppression medica
tion for elderly and disabled individuals
eliminated the income related disparity in
graft survival rates, we assumed that the
potential benefits of a coverage extension
to those currently ineligible would have
accrued to patients in the bottom three Zip
Code median income quartiles rather than
individuals in the highest income quartile,
who are likely to be able to afford the med
ication even after Medicare’s drug cover
age expires. We estimated the impact on
Medicare’s net cash flows by combining
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the cumulative cash outflows, determined
by the additional daily expenditures on
medication, with the cumulative daily cash
inflows, measured by the cost savings asso
ciated with avoiding graft failures. These
daily cumulative inflow and outflow values
are the summation of daily inflows and out
flows from January 1, 2000 to December
31, 2002.
Assuming a conservatively estimated
yearly cost of immunosuppression medi
cations of $8,000 gives an estimated daily
medication cost of $16.6 (assuming a
20-percent coinsurance rate). Using our
estimates of the extra costs associated with
graft failure, the estimated survival benefit
to the low income ineligibles, the numbers
of patients in each income cohort, and the
daily cost of immunosuppression medica
tion, we estimated the expected cost differ
ence to Medicare that would have occurred
if the lifetime coverage had been extended
to the ineligible patients in our sample.
We also considered how sensitive our
results would be to changes in parameter
values. Parameter subjected to this sensi
tivity analysis included: the daily cost dif
ferential between patients with functioning
grafts and those on maintenance dialysis,
the additional cost that occurs on the day
before graft failure, and the income related
disparity in kidney graft survival. We calcu
lated the impact on the cost effectiveness
ratios if we double each of the aforemen
tioned parameters one at a time, leaving
everything else constant.
reSUltS
We applied the methodology previously
discussed to calculate the number of graft
failures avoided and the impact on Medi
care’s cash flows from each transplant year
cohort broken down by income quartile.
Patients in the lowest income quartile
experienced the biggest difference in graft

survival compared to patients in the high
est income quartile, so this group would
experience the largest benefit from the
increased drug coverage. Patients trans
planted in 2001 experienced no graft sur
vival benefit in the year 2000, and patients
transplanted in 2002 experienced no graft
survival benefit in the years 2000 and 2001
because these cohorts had not yet been
transplanted. Similarly, with regard to the
extra cost of immunosuppression medi
cations, individuals transplanted in 1998
would not have incurred any additional
costs in the year 2000 because the year
2000 corresponds to this cohort’s third
post transplant year, for which they were
already eligible for coverage. Individu
als transplanted in 1999 would not have
incurred any additional costs until 2002,
and individuals transplanted in 2000, 2001,
and 2002 would not have incurred any addi
tional costs in 2000, 2001, or 2002 because
these years are within the existing 3-year
coverage window.
To illustrate the method by which accu
mulated costs and benefits were calculated,
Figure 3 shows graphically the calculation
for the cohort of patients transplanted
in 1998 belonging to the lowest income
quartile. By the end of 2002, outflows and
inflows for this cohort are roughly equal.
Among patients in this income quartile
transplanted in 1997 outflows are greater
than inflows in each year, and for patients
in this income quartile transplanted after
1998 inflows are greater than outflows.
Because patients in quartile 1 would have
experienced the largest improvement in
graft survival, this is the cohort of patients
most likely to demonstrate a net cost sav
ings over the period studied. We repeated
the same process for the other income
quartiles and transplant years to obtain our
accumulated net cash flows.
Results aggregated by transplant cohort
and income quartile suggest that in 2000,
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Figure 3 �
Cash Inflows and Outflows for Quartile 1 Patients Transplanted in 1998 �
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Date
NOTES:PatientsweredividedintoquartilesbasedonthemedianfamilyincomeoftheirZipCodefromthe2000
U.S.Census.Quartile1referstothelowestZipCodeincomequartile.
SOURCE:Page,T.F.,FloridaInternationalUniversity,andWoodward,R.S.,UniversityofNewHampshire,usingthe
2005U.S.RenalDataSystemrelease.

the increased medication coverage would
have resulted in 103 grafts saved in 2000,
138 additional grafts saved in 2001, and 167
additional grafts saved in 2002 (Table 2).
Net incremental cash flows to Medicare,
calculated as incremental inflows minus
incremental outflows would have totaled
-$2.40 million in 2000, -$7.82 million in
2001, and -$12.14 million in 2002 (Table 2).
These incremental benefit and incremen
tal cost estimates imply cost effectiveness
ratios of $23,251 per graft failure avoided in
2000, $56,712 avoided in 2001, and $72,684
avoided in 2002.
Given the large incremental costs to
Medicare of extending coverage to all
transplant recipients, we calculated the
incremental costs associated with extend
ing coverage only to patients residing in the
lowest Zip Code median income quartile
102

(Table 2). These patients would have expe
rienced the largest benefit of extended
coverage because the income related dis
parity for this group is the largest. Extend
ing coverage to only this group would have
resulted in a cost savings to Medicare of
$0.24 million in 2000, 0.78 million in 2001,
and $1.08 million in 2002. These results
are consistent with Kasiske et al. (2000),
who projected a cost savings assuming
only the lowest income patients receive
lifetime coverage.
Results of the sensitivity analyses con
ducted are reported in Table 2. Doubling
each parameter, one by one, did not pro
duce a cost savings assuming that individ
uals of all four income quartiles would be
eligible for the benefit. The parameters with
the largest impact were the income related
disparity in graft survival and the daily cost
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Table 2
Cost-Effectiveness Calculations Based on Accumulated Net Cash Flow Estimates
and Sensitivity Analysis of Key Parameter Values: 2000-2002

Year

Additional
Outflows
(Millions)

2000
2001
2002

$ 6.25
17.84
28.22

2000
2001
2002

$159
4.62
7.35

Cost
Savings
(Millions)

Number of
Grafts
Saved

Net
In/Outflow
(Millions)

Cost
Effectiveness

Coverage Extension to All Patients

$3.85
10.03
16.08

103
138
167

-$2.40
-7.82
-2.14

$ 23,251
56,712
72,684

Coverage Extension Limited to Patients in lowest Income Quartile

$1.83
5.41
844

$024
0.78
1.08

51
65
70

- $ 4,662
-12,010
-15,442

Sensitivity Analysis

2000
2001
2002

Baseline
Estimate

Daily Cost
Differential x 2

Additional Pre!
Post Failure
Costs x 2

$23,251
56,712
72,684

$ 4,074
11,591
3,786

$ 5,101
29,067
45,294

Income Related
Disparity x 2

$1,187
8,539

10,329

NOTE: Numbers in the bottom panel are cost effectiveness ratios obtained from the sensitivity analysis
SOURCE: Page, TF _, Florida International University, and Woodward, R.S, University ot New 11ampshire; using the 2005 U.S. Renal Data
System release

differential. Even using these implausibly
high benefit and low-eost parameter values,
we still obtained a net cost to Medicare.
Therefore, our main result, that extending
lifetime coverage to all transplant recipi
ents would have increased Medicare's
net costs, did not depend heavily on the
assumption we made in our analysis. These
calculations also suggest that for a cover
age extension to generate cost savings
after 2003 (data not available), there would
have to be dramatic changes in either the
characteristics of transplanted patients or
the costs of treatment.
CONCLUSION
Although we estimated a cost savings
when the coverage extension was applied
only to patients in the lowest income
quartile, these estimates must be inter
preted with caution. In reality, a proposal
to extend coverage to only patients in the
bottom income quartile would likely be
unpopular and perhaps deemed unfair.

Covering only the lowest income patients
would likely result in signilicant crowd
out, where higher income individuals may
decrease their labor supply to avoid having
to pay for the costly medications outcof
pocket. Lastly, the favorable cost effectivcL
ness ratios suggested by this exercise
depended heavily on the assumption that
the disparity between income quartiles 1
and 4 that appears during the second post
transplant year is related to the cancella
tion of coverage at the beginning of the
fourth post transplant year.
'Inroughout our analysis, we calculated
accumulated inflows and outtlows in 1
year cohorts and assumed that patients
were transplanted in the middle of the
year. 'Inis assumption did not change the
costs and benefits experienced by each
transplant-year cohort, but it could have
affected the distribution of these costs and
benefits for 2000, 2001, and 2002. We also
made conservative assumptions about the
additional cost of the medication, and gen
erous assumptions about the benefits of
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extended coverage. Therefore, these large
negative estimated cashflows should be
taken to represent best case estimates of
what would have occurred had Medicare
extended drug coverage to all transplant
recipients. Although Yen and colleagues
(2004) concluded that extending lifetime
coverage to all transplant patients would
produce a net societal savings, the current
study considered whether extending life
time coverage to all transplant recipients
would result in immediate cost savings
only to Medicare. Showing an immediate
cost savings to Medicare would present a
stronger argument for implementing such
a coverage extension, even in periods of
Federal budgetary shortfalls.
We found evidence to suggest that
extending Medicare’s lifetime coverage of
immunosuppression medications to all of
the non-elderly, non-disabled population
of kidney transplant recipients would have
resulted in a significant additional cost to
Medicare. Although there would have
been savings associated with avoiding graft
failure through increased drug coverage,
these incremental benefits would have been
heavily outweighed by the incremental
costs of covering all transplant recipients,
most of whom would have experienced no
improvement in graft survival outcomes.
Extending the coverage only to individu
als residing in the lowest Zip Code median
income quartile most likely to benefit from
extended coverage would have produced
cost savings to Medicare, although this
result would have depended heavily on the
generous assumptions regarding the medi
cal benefit to these individuals.
In this article, we considered only the
point of view of Medicare’s costs, the larg
est payer after transplantation. Although
this point of view is a natural starting point,
future investigations are needed to exam
ine the societal and patient perspectives,
104

which would incorporate improved quality
of life and labor market productivity
increases into the benefit measures. Add
ing these additional benefits of improved
outcomes to the analysis could suggest a
net societal benefit to extending lifetime
coverage to all transplant recipients.
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